Factors Influencing the Response to Interferon Therapy in Chronic Hepatitis C: Studies on Viral Genotype and Induction of 2′,5′-Oligoadenylate Synthetase in the Liver and Peripheral Blood Cells

Scandinavian Journal of Gastroenterology

Volumn 31, Issue 6, 1996, Pages 604-611

  Grander D ^b   Hultcrantz, R ^b   Weiland, O ^b   Xu, B ^b   Sangfelt, O ^b   Bjorklund A C ^b   Befrits, R ^b   Bjorkholm M ^b   Gruber, A ^b   Kinnman, N ^b   Reichard, O ^b   Widell, A ^b   Einhorn, S ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b NONE

Author keywords

2 ,5 oligoadenylate synthetase; Hepatitis C; Interferon; Predictive assay; Viral genotype

Indexed keywords

2',5' OLIGOADENYLATE SYNTHETASE; ALANINE AMINOTRANSFERASE; RECOMBINANT ALPHA2B INTERFERON;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CHRONIC HEPATITIS; DRUG EFFECT; DRUG EFFICACY; ENZYME ACTIVATION; ENZYME INDUCTION; HEPATITIS C; HUMAN; HUMAN CELL; IMMUNOTHERAPY; LIVER BIOPSY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; TREATMENT OUTCOME;

2',5'-OLIGOADENYLATE SYNTHETASE; ANTIVIRAL AGENTS; CELLS, CULTURED; ENZYME INDUCTION; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HEPATITIS, CHRONIC; HUMANS; INTERFERON ALFA-2B; INTERFERON-ALPHA; LEUKOCYTES, MONONUCLEAR; LIVER;

EID: 0029976669     PISSN: 00365521     EISSN: None     Source Type: Journal    
DOI: 10.3109/00365529609009135     Document Type: Article

References (30)

1. Dienstag J. Non-A, non-B hepatitis. I. Recognition, epidemiology, and clinical features. Gastroenterology 1983;85:439-62.
2. Weiland O. Interferon therapy in chronic hepatitis C virus infection. FEMS Microbiol Rev 1994;14:279-88.
3. Marcellin P, Boyer N, Giostra E, Degott C, Courouce A, Degos F, et al. Recombinant human alfa-interferon in patients with chronic non-A, non-B hepatitis: a multicenter randomized controlled trial from France. Hepatology 1991;13:393-7.
4. Kanai K, Kako M, Okamoto H. HCV genotypes in chronic hepatitis C and response to interferon. Lancet 1992;339:1543.
5. Yun ZB, Reichard O, Chen M, Lundeberg J, Norkrans G, Fryden A, et al. Serum hepatitis C virus RNA levels in chronic hepatitis C - importance for outcome of Interferon alfa-2b treatment. Scand J Infect Dis 1994;26:263-70.
6. Lengyel P. Mechanisms of interferon action: the (2′,5′) (A)n synthetase-RNase L pathway. In: Gresser I, editor. Interferon. London: Academic Press, 1981:78-99.
7. Kerr IM, Brown RE. PppA2′ p5′ A2′-5A: an inhibitor of protein synthesis synthesized with an enzyme fraction from interferon-treated cells. Proc Natl Acad Sci USA 1978;75:256-60.
8. Affabris E, Romeo G, Belardelli F, Jemma C, Mechti N, Gresser I, et al. 2,5-A synthetase activity does not increase in interferon-resistant Friend leukemia cell variants treated with α/β interferon despite the presence of high-affinity receptor sites. Virology 1983;125:508-12.
9. Marti J, Vandebussche P, Silhol M, Milhaud P, Verhaegen M, Content J, et al. Effects of interferon on sensitive and resistant L 1210 cell lines. J Interferon Res 1981;1:287-95.
10. Salzberg S, Wreshner DH, Oberman F, Panel A, Bakhananshvili M. Isolation and characterization of an interferon-resistant cell line deficient in the induction of (2′,5′) oligoadenylate synthetase activity. Mol Cell Biol 1983;3:1759-65.
11. Silverman RH, Krause D, Jacobsen J, Leisy SA, Barlow DP, Friedman RM. 2,5-A-dependent RNase levels vary with interferon treatment, growth rate and cell differentiation. In: DeMaeyer E, Schellekens H, editors. The biology of the interferon system. Amsterdam: Elsevier, 1983:189-200.
12. Tovey MG, Dron M, Mogensen KE, Lebleu B, Mechti N, Begon-Lours-Guymarho J. Isolation of Daudi cells with reduced sensitivity to interferon. II. On the mechanisms of resistance. J Gen Virol 1983;64:2649-53.
13. Grandér D, Öberg K, Lundqvist M-L, Tiensuu Janson E, Eriksson B, Einhorn S. Interferon-induced enhancement of 2′,5′-oligoadenylate synthetase in mid-gut carcinoid tumours. Lancet 1990;336:337-40.
14. Rosenblum MG, Maxwell BL, Talpaz M. In vivo sensitivity and resistance of CML cells to 2-IFN; correlation with receptor binding and induction of 2′,5′-oligoadenylate synthetase. Cancer Res 1986;46:4848-52.
15. Ferbus D, Khosravi S, Dumont J, Billard C. In vivo and in vitro induction of 2′,5′-oligoadenylate synthetase by interferon-alpha in nodular non-Hodgkin's lymphoma and correlations with the clinical response. J Biol Regul Homeostat Agents 1990;4: 127-34.
16. Einhorn S, Vanky F, Grandér D, Willems J. Induction of 2′-5′ oligoadenylate synthetase in malignant cells from freshly explanted tumor cells. Variability in the susceptibility to interferon. Eur J Cancer 1987;23:1607-13.
17. Okamoto H, Sugiyama Y, Okada S, Kurai K, Akahane Y, Sugai Y, et al. Typing hepatitis C virus by polymerase chain reaction with type specific primers: application to clinical surveys and tracing infectious sources. J Gen Virol 1992;73: 673-9.
18. Widell A, Shev S, Månsson S, Zhang YY, Foberg U, Norkrans G, et al. Genotyping of hepatitis C virus isolates by a modified PCR assay using type specific primers: epidemiological applications. J Med Virol 1994;44:272-9.
19. Chan SW, McOmish F, Holmes EC, Dow B, Peutherer JF, Follet E, et al. Analysis of a new hepatitis C virus type and its phylogenetic relationship to existing variants. J Gen Virol 1992; 73:1131-41.
20. Nousbaum J-B, Pol S, Nalpas B, Landais P, Berthelot P, Bréchot C. Hepatitis C virus type 1b (II) infection in France and Italy. Ann Intern Med 1995;122:161-8.
21. Gianelli G, Antonelli G, Fera G, Dianzani F, Schiraldi O. 2′,5′-oligoadenylate synthetase activity as a responsive marker during interferon therapy for chronic hepatitis C. J Interferon Res 1993;13:57-60.
22. Solinas A, Cossu P, Poddighe P, Tocco A, Deplano A, Garruciu G, et al. Changes of serum 2′,5′-oligoadenylate synthetase activity during interferon treatment of chronic hepatitis C. Liver 1993;13:253-8.
23. Pawlotzky JM, Hovanessian AG, Roudot-Thoraval F, Duvoux C, Bouvier M, Deforges L, et al. Is 2′-5′ oligoadenylate synthetase activity related to clinical response in to interferon therapy in patients with chronic hepatitis C? [abstract]. J Hepatol 1993;18:56.
24. Ballardini G, Groff P, Pontisso P, Giostra F, Francesconi R, Lenzi M, et al. Hepatitis C virus (HCV) genotype, tissue HCV antigens, hepatocellular expression of HLA-A,B,C and intracellular adhesion-1 molecules. J Clin Invest 1995;95:2067-75.
25. Pawlotzky JM, Hovanessian AG, Roudot-Thoraval F, Duvoux C, Bouvier M, Deforges L, et al. The activity of the interferon-dependent enzyme 2′-5′ oligoadenylate synthetase in patients with chronic hepatitis C [abstract]. J Hepatol 1993;18:53.
26. Levy DE, Lew DJ, Decker T, Kessler DS, Darnell JE. Synergistic interaction between interferon-α and interferon-γ through induced synthesis of one subunit of the transcription factor ISGF3. EMBO J 1990;9:1105-11.
27. Chemello L, Alberti A, Rose K, Simmonds P. Hepatitis C serotype and response to interferon therapy. N Engl J Med 1994;330:143.
28. Kobayashi Y, Watnabe S, Konishi M, Yokoi M, Kakehashi R, Kaitio M, et al. Quantitation and typing of serum hepatitis C virus RNA in patients with chronic hepatitis C treated with interferon-beta. Hepatology 1993;18:1319-25.
29. Foster GR, Achrill AM, Goldin RD, Kerr IM, Thomas HC, Stark GR. Expression of the terminal protein region of hepatitis B virus inhibits cellular response to interferons α and γ and double-stranded RNA. Proc Natl Acad Sci USA 1991;88:2888-92.
30. Gutch MJ, Reich NC. Repression of the interferon signal transduction pathway by the adenovirus E1A oncogene. Proc Natl Acad Sci USA 1991;88:7913-7.